The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Gemcitabine plus nab-paclitaxel versus gemcitabine alone in elderly patients aged 76 years or older with unresectable pancreatic cancer: A propensity score-matched multicenter prospective observational study.
 
Satoshi Kobayashi
Honoraria - Bayer Yakuhin; Eisai; GlaxoSmithKline; Kyowa Hakko Kirin; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takara Bio (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Motoko Suzuki
No Relationships to Disclose
 
Makoto Ueno
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Merck Serono; MSD; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Astellas Pharma; AstraZeneca (Inst); Chugai Pharma; Delta-Fly Pharma; Eisai (Inst); Incyte (Inst); JPH Clinical Development; Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Yuta Maruki
No Relationships to Disclose
 
Junji Furuse
Honoraria - Abbvie; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Fujifilm; Kyowa Hakko Kirin; Lilly Japan; Merck; Mochida Pharmaceutical Co. Ltd.; MSD; Mylan; Nihon Servier; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Shionogi; Shire; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Lilly Japan; Merck; MSD; Mundipharma; Novartis; OncoTherapy Science; Ono Pharmaceutical; Otsuka; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Takara Bio; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Akiko Todaka
Honoraria - Yakult Honsha
 
Masato Ozaka
Honoraria - AstraZeneca; Bayer; EA Pharma; Eisai; MSD; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha
 
Kunihiro Tsuji
No Relationships to Disclose
 
Kazuhiko Shioji
No Relationships to Disclose
 
Keitaro Doi
No Relationships to Disclose
 
Yasushi Kojima
Speakers' Bureau - Chugai Pharma
Research Funding - Eisai (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Takeda (Inst)
Expert Testimony - AstraZeneca
 
Hidetaka Tsumura
No Relationships to Disclose
 
Kazunari Tanaka
No Relationships to Disclose
 
Hajime Higuchi
No Relationships to Disclose
 
Ken Kawabe
No Relationships to Disclose
 
Takeharu Yamanaka
Honoraria - Bayer; Chugai Pharma; Takeda
Research Funding - Bayer (Inst); Chugai/Roche (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hiroshi Ishii
Honoraria - Lilly Japan; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Ono Pharmaceutical